TOVX · Theriva Biologics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $8.60M | $12.03M | $14.31M | $11.72M | $7.80M | $5.13M |
| SG&A | $15.45M | $7.40M | $7.12M | $9.86M | $6.47M | $5.03M |
| Total Operating Expenses | $24.05M | $26.35M | $21.43M | $21.58M | $14.27M | $10.16M |
| D&A | $108.0K | $137.0K | $135.0K | $85.0K | $87.0K | $201.0K |
| Operating Income | ($24.05M) | ($26.35M) | ($21.43M) | ($21.58M) | ($14.27M) | ($10.16M) |
| Interest Expense | $6.0K | - | - | - | - | - |
| Income Tax | - | $0 | ($1.64M) | ($1.43M) | $0 | $0 |
| Net Income | ($25.25M) | ($25.65M) | ($18.35M) | ($19.68M) | ($14.27M) | ($10.04M) |
| EPS - Basic | ($2.08) | ($19.03) | ($28.50) | ($32.75) | ($165.00) | - |
| EPS - Diluted | ($2.08) | ($19.03) | ($28.50) | ($32.75) | ($165.00) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.06M | $11.61M | $23.18M | $41.79M | $67.33M | $6.23M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.01M | $859.0K | $770.0K | $915.0K | $524.0K | $886.0K |
| Current Assets | $17.47M | $16.28M | $27.40M | $45.52M | $68.86M | $7.93M |
| Total Assets | $38.24M | $35.35M | $55.22M | $71.86M | $70.36M | $8.41M |
| Current Liabilities | $10.01M | $7.58M | $6.74M | $7.06M | $3.55M | $2.97M |
| Long-term Debt | $1.67M | $92.0K | $162.0K | $221.0K | - | - |
| Total Liabilities | $22.86M | $16.29M | $15.52M | $17.30M | $4.96M | $3.15M |
| Stockholders' Equity | $15.38M | $19.07M | $36.96M | $62.22M | $65.41M | ($4.77M) |
| Retained Earnings | ($358.71M) | ($334.97M) | ($309.32M) | ($290.97M) | ($271.28M) | ($248.09M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.67M) | ($16.94M) | ($19.00M) | ($19.08M) | ($12.89M) | ($12.17M) |
| Investing Cash Flow | ($35.0K) | ($1.0K) | ($202.0K) | ($4.40M) | ($14.0K) | ($9.0K) |
| Financing Cash Flow | $18.19M | $5.50M | $625.0K | ($1.93M) | $74.00M | $3.36M |
| CapEx | $35.0K | $1.0K | $202.0K | $116.0K | $14.0K | $9.0K |
| Free Cash Flow | ($16.70M) | ($16.94M) | ($19.20M) | ($19.20M) | ($12.90M) | ($12.18M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.66 | 0.66 | 1.05 | 0.98 | 0.90 | 1.21 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -66.0% | -72.6% | -33.2% | -27.4% | -20.3% | -119.4% |
| Return on equity | -164.1% | -134.5% | -49.6% | -31.6% | -21.8% | 210.7% |
| Return on invested capital | - | -108.6% | -45.6% | -27.3% | - | - |
| Liquidity | ||||||
| Current ratio | 1.74 | 2.15 | 4.07 | 6.45 | 19.37 | 2.67 |
| Quick ratio | 1.74 | 2.15 | 4.07 | 6.45 | 19.37 | 2.67 |
| Cash ratio | 1.30 | 1.53 | 3.44 | 5.92 | 18.94 | 2.10 |
| Leverage | ||||||
| Debt / Equity | 0.11 | 0.00 | 0.00 | 0.00 | - | - |
| Debt / Assets | 0.04 | 0.00 | 0.00 | 0.00 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -4008.5x | - | - | - | - | - |
| Equity multiplier | 2.49 | 1.85 | 1.49 | 1.15 | 1.08 | -1.76 |
| Liabilities / Assets | 0.60 | 0.46 | 0.28 | 0.24 | 0.07 | 0.37 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.2x | 0.1x | 4.7x | 2.8x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 8.7% | -22.9% | 0.7% | -51.2% | -40.5% | 35.1% |
| Net income growth (YoY) | 1.6% | -39.8% | 6.8% | -38.0% | -42.1% | 34.4% |
| EPS growth (YoY) | 89.1% | 33.2% | 13.0% | 80.2% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 1.4% | 11.8% | 0.0% | -48.8% | -6.0% | 12.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -19.3% | -48.4% | -40.6% | -4.9% | - | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Theriva Biologics against the 5 most active filers in the same SIC group.